Observational studyLung cancer (Amsterdam, Netherlands)2025
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.
Observational study in Lung cancer (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative EGFR-Targeted Therapy in Resectable EGFR-Mutated NSCLC: A Narrative Review from Drug Design to Pain-Informed MRD-Guided Care.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEGFR-inhibitors are currently not approved for neoadjuvant treatment of resectable EGFR-mutant non-small cell lung cancers (NSCLC). We report a real-world multi-institutional analysis of surgical and pathologic outcomes in patients with resectable EGFR-mutant NSCLC treated with neoadjuvant therapies.
methodsWe identified patients with clinical stage II-IIIB NSCLC with sensitizing EGFR mutations who received neoadjuvant osimertinib and/or platinum-based doublet chemotherapy with intent for definitive surgical resection. Clinicopathologic characteristics and treatment outcomes were annotated. Event-free survival (EFS) was defined from the start of neoadjuvant treatment.
resultsWe identified 51 patients who received neoadjuvant osimertinib (N = 23, 45 %), chemotherapy alone (N = 18, 35 %), or osimertinib and chemotherapy (N = 10, 20 %). R0 resection rates were 91 % with osimertinib, 72 % with chemotherapy, and 90 % with osimertinib and chemotherapy. Rates of pathologic complete response were 17 % with osimertinib, 0 % with chemotherapy, and 0 % with osimertinib and chemotherapy. Rates of major pathologic response were 44 % with osimertinib, 0 % with chemotherapy, and 10 % with osimertinib and chemotherapy. Pathologic tumor downstaging occurred in 48 % with osimertinib, 44 % with chemotherapy, and 40 % with osimertinib and chemotherapy; pathologic lymph node downstaging occurred in 35 % with osimertinib, 28 % with chemotherapy, and 40 % with osimertinib and chemotherapy. Median follow up time was 19 months. Median EFS was 61 months with osimertinib, 32 months with chemotherapy, and 20 months with osimertinib and chemotherapy.
conclusionsPathologic complete responses and major pathologic responses were only observed in patients with EGFR-mutant NSCLC treated with osimertinib. EGFR-inhibitors may play an important role in the preoperative management of EGFR-mutant lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.